Table of Content


Introduction
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Therapeutics Assessment
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Companies Involved in Therapeutics Development
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Drug Profiles
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or CP or SNCA) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by ABL Bio Inc, H1 2020
Pipeline by AC Immune SA, H1 2020
Pipeline by AFFiRiS AG, H1 2020
Pipeline by Annovis Bio Inc, H1 2020
Pipeline by Aprinoia Therapeutics Inc, H1 2020
Pipeline by Arvinas Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by Capo Therapeutics Inc, H1 2020
Pipeline by Declion Pharmaceuticals Inc, H1 2020
Pipeline by DegenRx BV, H1 2020
Pipeline by Denali Therapeutics Inc, H1 2020
Pipeline by Enterin Inc, H1 2020
Pipeline by Fulcrum Therapeutics Inc, H1 2020
Pipeline by Genmab AS, H1 2020
Pipeline by ICB International Inc, H1 2020
Pipeline by NeuBase Therapeutics Inc, H1 2020
Pipeline by Neurimmune Holding AG, H1 2020
Pipeline by Neuropore Therapies Inc, H1 2020
Pipeline by nLife Therapeutics SL, H1 2020
Pipeline by Prevail Therapeutics Inc, H1 2020
Pipeline by Priavoid GmbH, H1 2020
Pipeline by Primary Peptides Inc, H1 2020
Pipeline by Proclara Biosciences Inc, H1 2020
Pipeline by ProMIS Neurosciences Inc, H1 2020
Pipeline by Prothena Corp Plc, H1 2020
Pipeline by Seelos Therapeutics, Inc., H1 2020
Pipeline by Treventis Corp, H1 2020
Pipeline by UCB SA, H1 2020
Pipeline by United Neuroscience Ltd, H1 2020
Pipeline by Voyager Therapeutics Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020